GM Undershoots Estimates on Chip Dearth, Lifts Full-Year Outlook

(Bloomberg) — General Motors Co. missed analysts’ profit estimates for the latest quarter but raised its full-year guidance as rich margins on pickups vied with nagging production cuts at its North American factories from a global semiconductor shortage.

Soaring new-vehicle prices on high-margin pickups couldn’t make up for supply chain issues in the second quarter and expenses related to battery fires on its Chevrolet Bolt electric vehicle. But GM remained optimistic about its full-year earnings prospects, boosting its 2021 forecast Wednesday after signaling in June it would hit the high-end of its previous guidance.

The Detroit automaker now expects adjusted earnings before interest and taxes of $11.5 billion to $13 billion for all of 2021, which translates to adjusted earnings of $5.40 to $6.40 per share. That compares to an earlier projection for $10 billion to $11 billion, or $4.50 to $5.25 a share.

Shares of GM fell 2.9% in premarket trading to $56.20 as of 7:45 a.m. in New York. The stock had gained 39% this year as of the close Tuesday.

Chip Shortfall

Record average transaction prices for new vehicles pumped up profits, even as GM and other automakers struggled to keep plants open due to shortfalls in chip supplies. The company’s average new vehicle transaction price in July rose 9% from a year earlier — almost double the industry average of 4.8% — to an estimated $44,749, according to market researcher TrueCar.

But it hasn’t been able to make the most of that uptick in pricing due to limited vehicle inventories. GM disclosed on Tuesday that output of its Chevrolet Silverado and GMC Sierra full-size pickups — which it sold a combined 237,000 of last quarter — would be affected by another round of temporary factory closures in Michigan and Mexico through Aug. 16.

The automaker reported adjusted earnings per share of $1.97 for the second quarter, below the $2.08 a share analyst consensus forecast compiled by Bloomberg. That compares to a 50 cents a share adjusted loss a year ago while in the grips of the pandemic and the 13 cents a share archrival Ford Motor Co. posted last week for the latest quarter.

GM said it spent $800 million on a recall issued late last month for almost 69,000 Chevy Bolts due to the risk of fires from defective batteries made by South Korea’s LG Chem Ltd.

More stories like this are available on bloomberg.com

©2021 Bloomberg L.P.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

fatherhood and grandparenting
Bluegrass Bonds and Life Lessons: Fatherhood and Grandparenting with Mark Buerger
September 19, 2024

In an engaging episode of Grand Dads, host Tad Druart sits down with Mark Buerger, the Director of Communications and External Relations at the Special Olympics Kentucky for an insightful conversation on fatherhood and grandparenting that blends personal anecdotes, life lessons, and reflections on family, friendship, and sports. With warmth and humor, Buerger opens…

Read More
decarbonization efforts
Decarbonization Efforts and Goals in the Aerospace Industry
September 18, 2024

As the aerospace industry intensifies its focus on decarbonization efforts, the sector faces increasing pressure to reduce its carbon footprint in line with global climate goals. This conversation is particularly relevant as the industry contributes approximately 3.5% of global emissions. To stay competitive and comply with the Paris Agreement targets, aerospace companies are adopting…

Read More
Care Anywhere: The Journey Begins
Care Anywhere: The Journey Begins
September 18, 2024

In the inaugural episode of Care Anywhere: The Global Health Workforce Podcast, host Lea Sims, CMO of CGFNS International, Inc., introduces the organization’s mission to address global healthcare workforce challenges. Joining the discussion are Dr. Peter Preziosi, President and CEO of CGFNS International, Inc., and Julia To Dutka, Chief of the CGFNS Global Health Workforce…

Read More
revolutionizing drug development
Revolutionizing Drug Development: The Patient Voice is Leading the Way!
September 18, 2024

Revolutionizing drug development is pivotal in today’s healthcare landscape, particularly as the patient voice grows louder and more influential in shaping therapies. The latest episode of Healthcare Rethink, a FinThrive podcast, looks at this transformative trend. In an engaging discussion, host Brian Urban welcomes Wendy Erler, the VP of Global Patient Experience at Alexion…

Read More